How have XCUR shares performed in 2024?

Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR stock has decreased by 3.3% and is now trading at $0.5610. View the best growth stocks for 2024 here .

When is Exicure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our XCUR earnings forecast .

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) issued its earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The company had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million.

When did Exicure's stock split?

Exicure's stock reverse split on Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Exicure?

Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XCUR

Exicure (XCUR) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free XCUR Stock Alerts

$0.56

-0.02 (-3.44%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.56
▼
$0.60
50-Day Range: $0.55
▼
$0.74
52-Week Range: $0.36
▼
$1.50

Volume: 21,705 shs
Average Volume: 401,846 shs
Market Capitalization: $4.85 million

P/E Ratio: 0.33
Dividend Yield: N/A
Price Target: N/A

Get Exicure alerts:

Exicure MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$4.49 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.95 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Exicure.

4.0

Short Interest

Percentage of Shares Shorted
2.40% of the float of Exicure has been sold short.
Short Interest Ratio / Days to Cover
Exicure has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exicure has recently decreased by 1.53%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Exicure does not currently pay a dividend.
Dividend Growth
Exicure does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Exicure is -0.67.

2.6

News and Social Media Coverage

News Sentiment
Exicure has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Exicure this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exicure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,488,000.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Exicure is held by insiders.
Percentage Held by Institutions
42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Exicure is 0.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.47.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exicure is 0.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 267.30.
Price to Book Value per Share Ratio
Exicure has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

About Exicure Stock (NASDAQ:XCUR)

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

XCUR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XCUR Stock News Headlines

April 18, 2024 | americanbankingnews.com

Exicure (NASDAQ:XCUR) Shares Down 8.7%

February 22, 2024 | benzinga.com

Exicure Stock (NASDAQ:XCUR), Short Interest Report

April 20, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

February 6, 2024 | benzinga.com

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

February 6, 2024 | msn.com

Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

February 6, 2024 | msn.com

Exicure Inc Announces Licensing Patents for Therapeutic Advancement

February 5, 2024 | marketwatch.com

Exicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis Treatment

February 5, 2024 | finance.yahoo.com

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

April 20, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

February 1, 2024 | msn.com

Best Undervalued Stocks for February 2024

December 16, 2023 | ca.finance.yahoo.com

Exicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo Finance

December 8, 2023 | investorplace.com

Why Is Exicure (XCUR) Stock Up 57% Today?

November 28, 2023 | msn.com

Exicure receives Nasdaq delinquency notice on late filing of its form 10-Q

November 9, 2023 | morningstar.com

Exicure Inc XCUR

August 29, 2023 | finance.yahoo.com

Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop

August 23, 2023 | msn.com

Exicure names new CEO, CFO, directors in wake of resignations

August 15, 2023 | finance.yahoo.com

Exicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)

August 11, 2023 | marketwatch.com

Exicure: Substantial Financing Needed to Continue Operations

August 11, 2023 | businesswire.com

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 14, 2023 | finance.yahoo.com

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 26, 2023 | msn.com

Exicure board backs CEO Kim's strategic alternative view for company

May 26, 2023 | finance.yahoo.com

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 25, 2023 | sg.finance.yahoo.com

Exicure, Inc. (XCUR) stock price, news, quote & history – Yahoo Finance

May 19, 2023 | seekingalpha.com

Exicure gets Nasdaq non-compliance notice for not filing 10-Q

April 27, 2023 | finance.yahoo.com

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

March 28, 2023 | wsj.com

Exicure Warns of Need to Raise Additional Funds to Keep Operating

March 28, 2023 | finance.yahoo.com

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

See More Headlines

Receive XCUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/19/2021
Today: 4/19/2024
Next Earnings (Estimated): 7/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XCUR
CUSIP: N/A
CIK: 1698530
Web: www.exicuretx.com
Phone: (847) 673-1700
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 0.33
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $28.83 million
Price / Sales: 0.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: 0.19

Miscellaneous

Outstanding Shares: 8,650,000
Free Float: 8,311,000
Market Cap: $4.85 million
Optionable: Not Optionable
Beta: 1.31

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Paul Kang (Age 62)
CEO & Director
Ms. Jiyoung Hwang (Age 47)
CFO & Director
Mr. Joshua Miller (Age 48)
Chief Accounting Officer
Mr. Bart Anderson
Senior Director of R&D

Key Competitors

View All Competitors

Insiders

Co. Ltd. Dgp
Sold 3,400,000 shares
Total: $4.49 M ($1.32/share)

View All Insider Transactions

XCUR Stock Analysis - Frequently Asked Questions

How have XCUR shares performed in 2024?: Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR stock has decreased by 3.3% and is now trading at $0.5610.
View the best growth stocks for 2024 here.
When is Exicure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024.
View our XCUR earnings forecast.
How were Exicure's earnings last quarter?: Exicure, Inc. (NASDAQ:XCUR) issued its earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The company had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million.

When did Exicure's stock split?: Exicure's stock reverse split on Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Exicure?: Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XCUR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exicure (XCUR) Stock Price, News & Analysis

Exicure MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Exicure Stock (NASDAQ:XCUR)

XCUR Stock Price History

XCUR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

XCUR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™